Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Ivosidenib PFS Benefit in IDH1+ Cholangiocarcinoma Demonstrated in Newly Published Data

May 15th 2020

Ivosidenib induced a 63% reduction in the risk of disease progression or death versus placebo in previously treated patients with IDH1-mutant advanced cholangiocarcinoma, according to findings from the phase 3 ClarIDHy study published in the Lancet Oncology.

Ivosidenib PFS Benefit in IDH1+ Cholangiocarcinoma Demonstrated in Newly Published Data

May 14th 2020

Dr. Smaglo on Novel Therapies in Advanced Gastric Cancer

May 12th 2020

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Multidisciplinary Care Essential Amid Expanding HCC Armamentarium

May 11th 2020

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in hepatocellular carcinoma, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation in HER2+ Gastric Cancer

May 11th 2020

The FDA has granted a breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Multidisciplinary Care Essential Amid Expanding HCC Armamentarium

May 11th 2020

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in HCC, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm.

FDA Grants Trastuzumab Deruxtecan Breakthrough Designation in HER2+ Gastric Cancer

May 11th 2020

Multimodal Blood Test Successfully Screens for Advanced CRC, Adenomas

May 8th 2020

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Dr. Shah on Biomarkers of Response to Immunotherapy in Gastric/GEJ Cancer

May 8th 2020

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Locoregional Therapies Remain a Key Element of Care in HCC

May 8th 2020

Riad Salem, MD, discusses the role of localized therapy in hepatocellular carcinoma, the need to personalize treatment for patients, and the importance of implementing a multidisciplinary approach in this setting.

Making Headway in GI Malignancies in Miami

May 7th 2020

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

Trastuzumab Deruxtecan Submitted for Japanese Approval in HER2+ Gastric Cancer

May 7th 2020

A supplemental New Drug Application has been submitted to the Japanese Ministry of Health, Labour and Welfare seeking approval of trastuzumab deruxtecan for the treatment of patients with HER2-positive metastatic gastric cancer

Treatment Selection, Sequencing, and, Unmet Needs in GEP-NETs

May 7th 2020

Hagen F. Kennecke, MD, discusses treatment selection, peptide receptor radionuclide therapy, and remaining challenges in the field of gastroenteropancreatic neuroendocrine tumors.

Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC

May 7th 2020

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Dr. Simeone on Benefit of Neoadjuvant Gemcitabine in Pancreatic Cancer

May 7th 2020

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

FDA Grants MIV-818 Orphan Drug Status in HCC

May 6th 2020

The FDA has granted an orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal Adenocarcinoma

May 5th 2020

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Expert Explains Latest Treatment Strategies in GEP-NETs

May 5th 2020

Aman Chauhan, MD, discusses recent developments and emerging therapies in gastroenteropancreatic neuroendocrine tumors.

Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer

May 5th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the research he presented at the 2020 ACCR Virtual Annual Meeting and future areas of exciting efforts being made in pancreatic cancer.